Journal
PARKINSONISM & RELATED DISORDERS
Volume 84, Issue -, Pages 1-4Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.parkreldis.2020.12.020
Keywords
Uric acid; Biomarker; Glucocerebrosidase gene; Progression
Categories
Funding
- PPMI study, Parkinson's Progression Markers Initiative
- Michael J. Fox Foundation for Parkinson's Research
- Abbvie
- Avid
- Biogen
- Bristol-Myers Squibb
- Covance
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Lilly
- Lundbeek
- Merck
- Meso Scale Discovery
- Pfizer
- Piramal
- Roche
- Servier
- Teva
- UCB
- Golub Capital
Ask authors/readers for more resources
The study evaluated serum uric acid levels in PD patients with mutations in the GBA1 gene and found that these patients had lower uric acid levels compared to healthy controls over a 2-year period. This suggests that low serum uric acid might serve as a progression biomarker in GBA-PD, but further studies are needed to confirm this association.
Introduction: Blood uric acid represents an important biomarker in sporadic Parkinson's disease (PD). Whether uric acid levels change in genetic forms of PD is beginning to be assessed. The aim of the present study was to evaluate differences in serum uric acid level among PD patients harboring mutations in the glucocerebrosidase (GBA1) gene, sporadic PD, and healthy controls followed longitudinally. Methods: Longitudinal 2-year serum uric acid measurement data of 120 GBA-PD patients have been downloaded from the Parkinson's Progression Markers Initiative (PPMI) database. This cohort was compared with 369 de novo sporadic PD patients and 195 healthy controls enrolled in the same study. Results: Following adjustment for age, sex and BMI the GBA-PD cohort exhibited lower 2-year longitudinal uric acid level as compared to the controls (p = 0.016). Baseline uric acid measurements showed only a marginal difference (p = 0.119), but year 2 uric acid levels were lower in the GBA-PD cohort (p < 0.001). There was no difference in baseline, year 2 and 2-year longitudinal serum uric acid in the GBA-PD cohort as compared to sporadic PD (p = 0.664, p = 0.117 and p = 0.315). Conclusions: This is the first study to assess serum uric acid in a GBA-PD cohort. Our findings suggest that low serum uric acid might be a progression biomarker in GBA-PD. However, more studies (ideally longitudinal) on the association between low serum uric acid and clinical data in GBA-PD are needed. These results are consistent with data from previous reports assessing uric acid as a biomarker in other genetic forms of PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available